EXCERPT

LONDON and PHILADELPHIA and CAMBRIDGE, England, July 20, 2017 /PRNewswire/ — AMO Pharma Limited (“AMO Pharma”), a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, today announced it has entered into a Development and License Agreement with Numedicus Limited, a privately held UK biopharmaceutical company, to advance the development of a glutamate modulator (AMO-04) and related compounds for the treatment of Rett Syndrome and certain breathing disorders. The terms of the deal were not disclosed.

“AMO-04 is a unique drug with a long safety history that has shown significant promise as a potential treatment for Rett Syndrome based on screening by the Scout Program sponsored by Rettsyndrome.org and for certain breathing disorders based on research conducted by Numedicus collaborators. We are pleased that the program will continue to advance under this agreement with AMO Pharma,” said David Cavalla, chief executive officer of Numedicus.   

Numedicus was advised on the transaction by Shadow Lake Group Inc., a boutique life sciences advisory firm based in Toronto, Canada.

Read full news release here.